Boston Scientific CorporationBSXNYSE
Loading
EPS Growth Under PressureDecelerating
Percentile Rank38
Year-over-Year Change
Year-over-year earnings per share growth rate
Percentile
P38
Within normal range
vs 5Y Ago
-0.1x
Contraction
Streak
5 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -11.76% |
| Q3 2025 | -5.56% |
| Q2 2025 | 18.34% |
| Q1 2025 | 18.86% |
| Q4 2024 | 20.53% |
| Q3 2024 | 44.58% |
| Q2 2024 | -34.65% |
| Q1 2024 | -2.01% |
| Q4 2023 | -0.23% |
| Q3 2023 | 91.02% |
| Q2 2023 | -13.60% |
| Q1 2023 | 137.39% |
| Q4 2022 | -27.57% |
| Q3 2022 | -29.40% |
| Q2 2022 | 153.46% |
| Q1 2022 | 21.03% |
| Q4 2021 | -80.27% |
| Q3 2021 | 135.04% |
| Q2 2021 | -47.51% |
| Q1 2021 | 138.37% |
| Q4 2020 | 181.88% |
| Q3 2020 | -8.95% |
| Q2 2020 | -1472.15% |
| Q1 2020 | -99.72% |
| Q4 2019 | 3070.35% |
| Q3 2019 | -17.82% |
| Q2 2019 | -64.52% |
| Q1 2019 | 10.71% |
| Q4 2018 | -9.68% |
| Q3 2018 | -22.50% |
| Q2 2018 | 81.82% |
| Q1 2018 | 148.89% |
| Q4 2017 | -314.29% |
| Q3 2017 | 90.91% |
| Q2 2017 | -47.62% |
| Q1 2017 | 133.33% |
| Q4 2016 | -47.06% |
| Q3 2016 | 213.33% |
| Q2 2016 | -200.00% |
| Q1 2016 | 236.36% |